Tags |
|
|
Links |
|
|
Advice You - Sarbanes Oxley - The Resolution Or The Cause
Last year a 15 member commission was created by the US Chamber of Commerce to evaluate the
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
effects of litigation & regulation on the US capital market. Tom Donohue, the CEO of the C
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
hamber, is a powerful business lobbyist that has become critical of the implementation of S
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
arbanes Oxley (SarBox) especially section 404 which covers the assessment of internal contr
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ols.
The question remains: Is the litigious US business environment drivi
The question remains: Is the litigious US business environment drivi
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
g away foreign investment in US public companies? Has the SarBox section 404 caused these
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
declines and how could it be changed to build confidence but retain assurance of the effici
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ency of internal controls?
Despite the criticisms in the report, the Securi
Despite the criticisms in the report, the Securi
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ties and Exchange Commission's (SEC) Christopher Cox has responded with an acknowledgement
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
of the difficulties of SarBox but an emphasis on the new changes. The Complete Act of 2007
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
recommends a limitation of section 404 that only requires the internal control audit on a t
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
hree year basis. Another change proposed attempts to reduce the costs of these 404 audits
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
for smaller companies by making them voluntary. There is also a movement to rely more heav
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ily on the internal audit function for an assessment of lower risk internal controls.
By c
By c
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
hanging the rules for implementation the SEC feels that it would appropriately mitigate the
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
costs to firms for their audit AND reduce their exposure to unwarranted securities fraud la
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
wsuits. This is important to keeping the confidence of foreign and domestic investors but
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
also to the public companies that must adhere to these strict regulations. It will continu
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
e to be a concern for foreign companies wanting to enter into the US capital market. The S
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
EC's ultimate response will have a significant impact on the future of US public investment
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/5354/adviceyou-Sarbanes-Oxley--The-Resolution-Or-The-Cause.html">Sarbanes Oxley - The Resolution Or The Cause</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/5354/adviceyou-Sarbanes-Oxley--The-Resolution-Or-The-Cause.html]Sarbanes Oxley - The Resolution Or The Cause[/url]
Related Articles:
Stop Throwing Money Away In Your IT Department
Using Fabrics in Your Displays
Bookmark it:
|